CN118973574A - 异丁司特治疗新冠肺炎后遗症的用途 - Google Patents

异丁司特治疗新冠肺炎后遗症的用途 Download PDF

Info

Publication number
CN118973574A
CN118973574A CN202380026154.5A CN202380026154A CN118973574A CN 118973574 A CN118973574 A CN 118973574A CN 202380026154 A CN202380026154 A CN 202380026154A CN 118973574 A CN118973574 A CN 118973574A
Authority
CN
China
Prior art keywords
day
ibudilast
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380026154.5A
Other languages
English (en)
Chinese (zh)
Inventor
松田和子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of CN118973574A publication Critical patent/CN118973574A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380026154.5A 2022-02-01 2023-01-31 异丁司特治疗新冠肺炎后遗症的用途 Pending CN118973574A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263305483P 2022-02-01 2022-02-01
US63/305,483 2022-02-01
PCT/US2023/011931 WO2023150093A1 (en) 2022-02-01 2023-01-31 Ibudilast for use in the treatment of post-covid conditions

Publications (1)

Publication Number Publication Date
CN118973574A true CN118973574A (zh) 2024-11-15

Family

ID=85382992

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380026154.5A Pending CN118973574A (zh) 2022-02-01 2023-01-31 异丁司特治疗新冠肺炎后遗症的用途

Country Status (6)

Country Link
US (1) US12171752B2 (https=)
EP (1) EP4472631A1 (https=)
JP (1) JP2025504984A (https=)
CN (1) CN118973574A (https=)
CA (1) CA3251194A1 (https=)
WO (1) WO2023150093A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395747B1 (en) 1998-08-10 2002-05-28 Sauro Sakoda Remedies for multiple sclerosis
JP4954085B2 (ja) 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
US20090197823A1 (en) 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
WO2007142924A1 (en) 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
US8138201B2 (en) 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
CA3174413A1 (en) 2020-04-06 2021-10-14 Yuichi Iwaki Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
GB202005890D0 (en) * 2020-04-22 2020-06-03 Aivivo Ltd New uses
WO2022181219A1 (ja) 2021-02-24 2022-09-01 国立大学法人九州大学 新興ウイルス感染症治療薬

Also Published As

Publication number Publication date
EP4472631A1 (en) 2024-12-11
JP2025504984A (ja) 2025-02-19
WO2023150093A1 (en) 2023-08-10
US12171752B2 (en) 2024-12-24
US20230285367A1 (en) 2023-09-14
CA3251194A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
US10787502B2 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
CN108721265B (zh) 通过给予秋水仙碱衍生物治疗或预防心血管事件
US11612574B2 (en) Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
BRPI0616344A2 (pt) mÉtodo para o tratamento de dependÊncia quÍmica e comportamental
WO2012140504A1 (en) Therapeutic compounds
CN118973574A (zh) 异丁司特治疗新冠肺炎后遗症的用途
WO2019159176A1 (en) Compositions and methods for treatment of neurodegenerative diseases
AU2014249530B2 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
JP2024524434A (ja) うつ状態を処置するための方法
JP6878596B2 (ja) Ｆｘｒアゴニストの組合せ
JP2010506904A (ja) 精神障害の治療における抗精神病薬およびテトラサイクリンの併用療法
RU2432161C1 (ru) Новые комбинации нерамексана для лечения нейродегенеративных расстройств
US20210177812A1 (en) Methods of suppressing myeloid-derived suppressor cells in patients
US20230090534A1 (en) Methods of treating glioblastoma multiforme using combination therapy
US12005049B2 (en) Methods of preventing cancer metastasis
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
WO2017106584A1 (en) Treatment of central nervous system and mental disorders with agonists of beta-3 adrenoceptor
HK1250916A1 (zh) Aerd/哮喘中的血栓烷受体拮抗剂
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
MX2014002965A (es) Combinaciones que comprenden un modulador del receptor de s1p.
HK40011695B (en) Norketotifen for treatment of hypercytokinemia and viral infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination